By: Michael Rigas, Pharm.D., FNHIA Biosimilars are also known as follow-on biologics or subsequent-entry biologics. They are FDA-approved copies of the original “innovator” drug product that are allowed to be licensed and approved by the FDA once the innovator product’s patent expires. The Biologics Price and Competition Act (BPCA)...
Biosimilars 101 for AIC Organizations
